Search - tctmd.com

Displaying 21 - 40 of 79

Sort: Relevancy | Date

Presentation ACC 2024

Primary Results from the Phase 2 KARDIA-2 Study

Presenter: Akshay Desai

April 07, 2024

Presentation ACC 2024

Mandibular Advancement versus CPAP for BP Reduction in OSA and High Cardiovascular Risk

Presenter: Ronald Chi Hang Lee

April 06, 2024

Presentation Miami Valves 2024

Management of Pulmonary Hypertension: Cardiology Perspective

Presenter: Mrudula R. Munagala

February 01, 2024

Presentation Miami Valves 2024

Turning Point in Hypertension Care

Presenter: Maria Delgado-Lelievre

February 01, 2024

Presentation Controversies and Advances 2023

Renal Denervation Will Be an Option for Most Hypertensive Patients!

Presenter: Michael J. Bloch

November 30, 2023

Presentation AHA 2023

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Presenter: Jamie Kitt

November 17, 2023

Presentation AHA 2023

Hypertension Treatment in Nigeria: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

Presenter: Dike Ojji

November 17, 2023

Presentation AHA 2023

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

Presenter: Jing Li

November 16, 2023

Presentation

RDN to treat Resistant Hypertension

Presenter: Tai Kobayashi

November 10, 2023

Presentation EuroPCR 2023

Effectiveness and Safety of the NetrodTM Six-Electrode Radiofrequency Renal Denervation System for the Treatment of Uncontrolled Essential Hypertension

Presenter: Yu-Jie Zhou

May 17, 2023

Presentation ACC 2023

The STELLAR Phase 3 Trial: A Study of Sotaterceptin Combination with Background Therapy for the Treatment of Pulmonary Arterial Hypertension

Presenter: Marius M. Hoeper

March 05, 2023

Presentation Miami Valves 2023

What’s New In Renal Denervation?

Presenter: Sergio Perez

February 04, 2023

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

Presentation EuroPCR 2022

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Presenter: Felix Mahfoud

May 20, 2022

Presentation EuroPCR 2022

Patient-Level Pooled Analysis of Ultrasound RDN in RADIANCE-HTN SOLO and TRIO

Presenter: Ajay J. Kirtane, Michel Azizi

May 17, 2022

Presentation ARCH 2022

Anesthesia Update: Dealing with High-Risk Pulmonary Hypertension Patients

Presenter: Jonathan Zoller

April 23, 2022

Presentation ARCH 2022

Current Status and Future of Renal Denervation for Hypertension

Presenter: Tim A. Fischell

April 23, 2022

Presentation ACC 2022

The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery

Presenter: Maura Marcucci

April 04, 2022

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

Presentation ACC 2021

Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill: The Randomized Sham Controlled RADIANCE-HTN TRIO Trial

Presenter: Ajay J. Kirtane

May 16, 2021

Advertisement

Primary Results from the Phase 2 KARDIA-2 Study

Mandibular Advancement versus CPAP for BP Reduction in OSA and High Cardiovascular Risk

Management of Pulmonary Hypertension: Cardiology Perspective

Turning Point in Hypertension Care

Renal Denervation Will Be an Option for Most Hypertensive Patients!

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Hypertension Treatment in Nigeria: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

RDN to treat Resistant Hypertension

Effectiveness and Safety of the NetrodTM Six-Electrode Radiofrequency Renal Denervation System for the Treatment of Uncontrolled Essential Hypertension

The STELLAR Phase 3 Trial: A Study of Sotaterceptin Combination with Background Therapy for the Treatment of Pulmonary Arterial Hypertension

What’s New In Renal Denervation?

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Patient-Level Pooled Analysis of Ultrasound RDN in RADIANCE-HTN SOLO and TRIO

Anesthesia Update: Dealing with High-Risk Pulmonary Hypertension Patients

Current Status and Future of Renal Denervation for Hypertension

The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill: The Randomized Sham Controlled RADIANCE-HTN TRIO Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content